Back to Results
First PageMeta Content
Organic chemistry / Medicine / Amides / Merck / Oxadiazoles / Raltegravir / Integrase / Dolutegravir / ViiV Healthcare / Integrase inhibitors / Chemistry / Organofluorides


Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside
Add to Reading List

Document Date: 2014-11-03 11:26:24

Open Document

File Size: 46,87 KB

Share Result on Facebook

City

Osaka / London / Atlanta / /

Company

ViiV Healthcare / Shionogi-ViiV Healthcare LLC / Shionogi & Co. Ltd. / Corporate Communications Shionogi & Co. Ltd. / /

Country

Japan / United States / Canada / /

Event

Business Partnership / FDA Phase / /

/

IndustryTerm

foreign healthcare reforms / with respect to product / /

MedicalCondition

HIV infection / HIV / Opportunistic Infections / /

Organization

European Union / United States Food and Drug Administration / /

Person

Isao Teshirogi / Dominique Limet / /

/

Position

President & CEO / Chief Executive Officer / /

Product

Integrase Inhibitor / SPRING-2 / /

SocialTag